#Denmark #Copenhagen #Adcendo ApS #antibody-drug conjugates #Tissue Factor

Adcendo ApS Reports on Pipeline Progress

Adcendo ApS, headquartered in Copenhagen and Boston, has recently made significant strides in its clinical programs, focusing on antibody-drug conjugates (ADCs) that are not just groundbreaking but also aimed at treating cancers with substantial unmet needs. As a clinical-stage biotechnology company, Adcendo has been at the forefront of innovative cancer therapies, and the latest updates from their research pipeline are promising.

Key Advancements in Clinical Trials

Most notably, Adcendo's ADC known as ADCE-T02, which is designed to target Tissue Factor (TF), has progressed into the cohort expansion section of its Tiffany-01 clinical trial. This trial focuses on patients with advanced solid tumors, including types such as non-small cell lung cancer and head and neck squamous cell carcinoma. The current phase intends to optimize dosages while comprehensively assessing safety and efficacy. It holds potential to demonstrate enhanced therapeutic effects due to its unique targeting mechanism, which minimizes impact on healthy tissues.

The outcomes from this trial are expected to bolster the clinical proof of concept, further informing the ADC's therapeutic profile in treating various tumor types. In conjunction with these clinical advancements, Adcendo showcased significant preclinical findings at the recent American Association for Cancer Research (AACR) 2026 Annual Meeting. These findings, which demonstrated the strong efficacy of ADCE-T02 in preclinical models, reflect the promising potential of this ADC class in addressing complex cancer treatments.

Publications and Regulatory Designations

The robustness of ADCE-T02’s capabilities led to its highlight at the AACR meeting, where it was listed for a poster presentation. The poster, titled "ADCE-T02 - A clinical stage antibody drug conjugate targeting tissue factor demonstrates strong efficacy in preclinical models of head and neck squamous cell carcinoma," carries significant implications for the drug’s future clinical applications.

Additionally, a manuscript about ADCE-T02's preclinical data has also been published in Molecular Cancer Therapeutics, detailing its superior efficacy compared to previous designs. The results were particularly encouraging regarding the ADC's safety profile, which showed a lack of ocular or lung toxicity among tested non-human primates, suggesting a promising safety window for human patients.

Adcendo is equally excited about its ADCE-D01 ADC, which targets uPARAP, specifically designed for tumors of mesenchymal origin like soft tissue sarcomas. Recently, ADCE-D01 received Orphan Drug Designation from the U.S. FDA, providing the ADC with certain regulatory advantages as it moves forward in clinical trials.

Future Directions and Goals

Further emphasizing its commitment to advancing cancer care, Adcendo has initiated the first-in-human trial for ADCE-B05, which targets a novel entity overexpressed in squamous cell tumors. This trial is currently active across sites in the U.S. and Australia, and the first patient has already been dosed, marking another noteworthy milestone for the company.

Dr. Lone Ottesen, Chief Medical Officer at Adcendo, expressed great enthusiasm for the significant advances across the company’s ADC pipeline. With three separate Phase I trials enrolling patients and the successful closure of a recent Series C financing round, Adcendo aims to expedite its clinical programs, prioritizing the development of innovative treatment options for cancer patients facing limited choices.

In conclusion, Adcendo ApS is making impressive progress in its pipeline of antibody-drug conjugates, enhancing its stature within the biotechnology sector as a leader in cancer treatment innovation. With a focus on both efficacy and safety, Adcendo is aligning its resources and expertise to bridge the gap in cancer therapies and is poised to make meaningful contributions to patient care in the near future. For those wishing to learn more about Adcendo’s ongoing developments, further details can be found at Adcendo's Official Website.